Sandbox

Do Not Delete

Class I

a. LDL-C should be <100 mg/dL. (Level of Evidence: A)

b. If baseline LDL-C is ≥100 mg/dL, initiate LDL-lowering drug therapy. (Level of Evidence: A)

c. If on-treatment LDL-C is ≥100 mg/dL, intensify LDL-lowering drug therapy (may require LDL-lowering drug combination). (Level of Evidence: A)

d. If triglycerides are 200 to 499 mg/dL, non-HDL-C should be <130 mg/dL. (Level of Evidence:B)

e. Therapeutic options to reduce non HDL - C are more intense LDL - C lowering therapy. (Level of Evidence:B)

---

Class III (No Benefit)

1. Genetic testing is not indicated in relatives when the index patient does not have a definitive pathogenic mutation. (Level of Evidence: B)

2. Ongoing clinical screening is not indicated in genotype-negative relatives in families with HOCM. (Level of Evidence: B)

---

Class IIa

a. Reduction of LDL-C to <70 mg/dL is reasonable. (Level of Evidence:A)

b. If baseline LDL-C is 70 to 100 mg/dL, it is reasonable to treat to LDL-C <70 mg/dL. (Level of Evidence:B)

c. If triglycerides are 200 to 499 mg/dL, reduction of non-HDL-C to <100 mg/dL is reasonable. (Level of Evidence:B)

d. Therapeutic options to reduce non HDL - C are Niacin (after LDL-C loweing therapy). (Level of Evidence:B)

e. Therapeutic options to reduce non HDL - C are Fibrate therapy (after LDL-C loweing therapy). (Level of Evidence:B)

---

Shown below is a strip from a patient being cardioverted for atrial fibrillation. The patient was taking sotalol and coumadin. This is the first shock which was set at 150 joules and delivered via defibrillator pads placed with the positive in the V1 position and the negative on the back between the left scapula and the spine.

---